Lynx Investment Advisory’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
Lynx Investment Advisory's BMY Position: Q2 2026 in Review
Lynx Investment Advisory increased its Bristol-Myers Squibb (BMY) stake by 1.2% in Q2 2026, buying an estimated $3.85K and bringing the position to 5,540 shares worth $319K. The position accounts for 0.1% of the portfolio, ranked #176.
Lynx Investment Advisory first reported a position in BMY in Q2 2024 and has held it in 3 quarters since. The position peaked at $332K in Q1 2026. 2,517 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Lynx Investment Advisory held 5,540 shares of Bristol-Myers Squibb worth $319K as of Q2 2026.
- Lynx Investment Advisory bought 67 Bristol-Myers Squibb shares in Q2 2026, an estimated $3.85K.
- Bristol-Myers Squibb made up 0.1% of Lynx Investment Advisory's portfolio in Q2 2026, its #176 holding.
- Lynx Investment Advisory first reported a position in Bristol-Myers Squibb in Q2 2024 and has held it in 3 quarters since.
- Lynx Investment Advisory's Bristol-Myers Squibb position peaked at $332K in Q1 2026.
- 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Lynx Investment Advisory's 13F filing for Q2 2026, filed 27 Jul 2026.